RAC1 Regulates SHH-Medulloblastoma Growth via GLI-Mediated Transcription

Background Medulloblastoma (MB) is the most common malignant brain tumor of childhood, and current treatments cannot sufficiently inhibit tumoral growth, leptomeningeal dissemination, and metastasis. RAC1, a low molecular weight GTPase involved in cytoskeletal regulation and cell migration, is established to facilitate tumorigenesis in other neoplasia, but RAC1 is unexplored in MB and has no targeted therapies. Methods We examined RAC1 activity in SHH-subtype MB using human and mouse Ptch1 -/- cell models, RNAi knockdown, pharmacologic inhibition with GYS32661, transcript profiling, chromatin immunoprecipitation, and cytotoxicity assays in primary human astrocytes. We also determined the efficacy, brain penetration, and toxicity of GYS32661 in orthotopic spheroid Ptch1 -/- mouse and rat models. Results RAC1 activity was markedly increased in the MB tissue compared to the normal cerebellum. RAC1 depletion suppressed the proliferation and migration of SHH-MB cells. Mechanistically, RAC1 regulated GLI1 and GLI2 expression and bound the upstream loci of GLI1 and DNMT1, revealing a novel mechanism of SHH transcriptional regulation. GYS32661, a brain-permeable RAC1 inhibitor, was not toxic to normal astrocytes, suppressed SHH-MB tumor growth, and improved survival in vivo without toxicity in rats. Conclusion RAC1 functions as a critical transcriptional regulator of SHH signaling and epigenetic mediators in medulloblastoma, highlighting its potential as a druggable target in SHH-dependent MB. Our findings also characterize the RAC1 inhibitor GYS32661 as a promising drug candidate for the treatment of SHH-MB.